Aktienanalyse zu Sellas Life Sciences Group Inc (SLS)SLSSellas Life Sciences Group Inc

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sellas Life Sciences Group Inc is a good buy right now due to its current price of $11.65, which is significantly below the analyst price target of $30, suggesting a potential upside of over 157%. Additionally, the stock has shown a remarkable year-to-date change of +167.82%, indicating strong investor interest and momentum. However, the main risk is the ongoing negative net income, which reached -9,605,000 USD in Q2 2026, highlighting the company's financial challenges.